UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 17, 2005
--------------------
PharmaFrontiers Corp.
(Exact Name of Registrant as Specified in Its Charter)
------------------------------------------------------
Texas
-----
(State or Other Jurisdiction of Incorporation)
000-25513 76-0333165
--------- ----------
(Commission File Number) (I.R.S. Employer Identification No.)
2635 Crescent Ridge Drive
The Woodlands, Texas 77381
-------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (281) 272-9331
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.
On October 17, 2005, Brooks Boveroux was elected to the Board of
Directors. Mr. Boveroux will serve on the Board's Audit Committee. Mr. Boveroux
entered into a standard director's agreement whereby he received ten year
options to purchase 52,500 shares of Company common stock at an exercise price
per share of $1.15 for agreeing to serve on the Board and the Audit Committee.
There is no other arrangement or understanding between Mr. Boveroux and any
other person pursuant to which Mr. Boveroux was selected as a director. Mr.
Boveroux has not been involved with a related transaction or relationship as
defined by Item 404(a) of Regulation S-B between the Company and him.
Item 9.01 Financial Statements and Exhibits
(c) Exhibit 99.1
The following exhibits are to be filed as part of this 8-K:
Exhibit No. Description
99.1 Press release issued October 18, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMAFRONTIERS CORP.
By: /s/ David B. McWilliams
---------------------------
David B. McWilliams, Chief Executive Officer
DATE: October 19, 2005
EXHIBIT LIST
Exhibit No. Description
99.1 Press release issued October 18, 2005
End of report